|
gptkbp:instanceOf
|
gptkb:chemical_compound
gptkb:drug
reversible inhibitor of monoamine oxidase A
|
|
gptkbp:approvedBy
|
gptkb:Australia
gptkb:Canada
gptkb:Europe
1983
|
|
gptkbp:ATCCode
|
N06AG02
|
|
gptkbp:bioavailability
|
60%
|
|
gptkbp:brand
|
gptkb:Aurorix
gptkb:Manerix
gptkb:Moclodura
|
|
gptkbp:CASNumber
|
71320-77-9
|
|
gptkbp:chemicalClass
|
benzamide
|
|
gptkbp:compatibleWith
|
gptkb:United_States
|
|
gptkbp:contraindication
|
gptkb:pheochromocytoma
severe liver impairment
|
|
gptkbp:developedBy
|
gptkb:Hoffmann-La_Roche
|
|
gptkbp:drugInteraction
|
gptkb:tricyclic_antidepressants
gptkb:SSRIs
gptkb:meperidine
gptkb:selegiline
|
|
gptkbp:eliminationHalfLife
|
2 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:hasMolecularFormula
|
C13H17ClN2O2
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Moclobemide
|
|
gptkbp:IUPACName
|
4-chloro-N-(2-morpholin-4-ylethyl)benzamide
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
reversible inhibition of monoamine oxidase A
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
B3 (Australia)
|
|
gptkbp:proteinBinding
|
50%
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
dizziness
headache
insomnia
dry mouth
|
|
gptkbp:synonym
|
gptkb:Ro_11-1163
|
|
gptkbp:usedFor
|
gptkb:depression
gptkb:social_anxiety_disorder
|
|
gptkbp:bfsParent
|
gptkb:Antidepressants
|
|
gptkbp:bfsLayer
|
6
|